Abstract
Radiation (telegamma-therapy (TGT)) and chemoradiation (MPF + leucovorin (methotrexate + 5-fluorouracil + platidiam + leucovorin) treatments were comparatively analyzed in patients with Stages III-IV laryngopharyngeal cancer. Multidrug therapy + TGT were shown to be the method of choice when the patients refused to have combination treatment or when there were contraindications to surgery: 5-year overall survival was 46.4% versus 22.3% after TGT. Following the latter, the quality of life was significantly worse than that after chemoradiation therapy: 100% activity persisted only in 9.6 and 53.8% in Groups 1 and 2, respectively. This was due to the low indirect therapeutic effect of standard TGT and an early recurrence after it - 60% of the recurrences were detected within the first year following TGT while after chemoradiation, 66.7% of them occurred following 12 months or more.